TY  - GEN
AU  - Steigbigel,Roy T
AU  - Cooper,David A
AU  - Teppler,Hedy
AU  - Eron,Joseph J
AU  - Gatell,Jose M
AU  - Kumar,Princy N
AU  - Rockstroh,Jurgen K
AU  - Schechter,Mauro
AU  - Katlama,Christine
AU  - Markowitz,Martin
AU  - Yeni,Patrick
AU  - Loutfy,Mona R
AU  - Lazzarin,Adriano
AU  - Lennox,Jeffrey L
AU  - Clotet,Bonaventura
AU  - Zhao,Jing
AU  - Wan,Hong
AU  - Rhodes,Rand R
AU  - Strohmaier,Kim M
AU  - Barnard,Richard J
AU  - Isaacs,Robin D
AU  - Nguyen,Bach-Yen T
TI  - Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials
SN  - 1537-6591
PY  - 2010///0421
KW  - Anti-HIV Agents
KW  - adverse effects
KW  - CD4 Lymphocyte Count
KW  - Double-Blind Method
KW  - Drug Resistance, Viral
KW  - Drug Therapy, Combination
KW  - Female
KW  - HIV Infections
KW  - drug therapy
KW  - HIV-1
KW  - drug effects
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Pyrrolidinones
KW  - RNA, Viral
KW  - blood
KW  - Raltegravir Potassium
KW  - Viral Load
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1086/650002
ER  -